Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Survodutide

SYNCHRONIZE-1

Boehringer Ingelheim · Phase 3 · Completed · Enrollment 726

NCT06066515

Y axis: Change in body weight from baseline, %

0-5-10-15048121620243648607284Survodutide 3.6 mg, week 76, -12.2%Survodutide 3.6 mgSurvodutide 6.0 mg, week 76, -13%Survodutide 6.0 mgPlacebo, week 76, -5.4%Placebo

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Survodutide 3.6 mg: week 76 -12.2%
  • Survodutide 6.0 mg: week 76 -13%
  • Placebo: week 76 -5.4%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.